Skip to content

About Regenerative Medical Solutions

Advancing stem cell therapy for diabetes.

Regenerative Medical Solutions (RMS) is a privately held biotechnology company based in Madison, Wisconsin. Founded in 2012, RMS originated from pioneering academic research at the University of Wisconsin–Madison and is focused on developing a functional cure for diabetes using human induced pluripotent stem cell (iPSC) technology.

As a regenerative medicine company, RMS is committed to translating breakthrough diabetes research into scalable therapeutic solutions that aim to restore the body’s natural insulin production. Our mission is rooted in scientific rigor, ethical innovation, and a long-term vision to transform diabetes treatment worldwide.

Our Mission: To Develop a Cure for Diabetes Through Regenerative Medicine

Diabetes is one of the most significant global health challenges, affecting hundreds of millions of people and placing a substantial financial burden on healthcare systems worldwide. Current diabetes treatment options primarily manage symptoms through insulin administration and glucose monitoring. While lifesaving, these approaches do not address the underlying loss or dysfunction of insulin-producing cells.

Our stem cell therapy for diabetes seeks to regenerate or replace the pancreatic beta cells responsible for insulin production. At RMS, our goal is to develop a cure for diabetes by restoring natural insulin function using regenerative medicine techniques.

Our work focuses on:

    • Advancing iPSC therapy to generate insulin-producing cells
    • Reducing reliance on donor pancreases
    • Creating scalable solutions suitable for broad patient populations
    • Maintaining ethical, non-embryonic stem cell practices
    • Designing a therapeutic approach intended to eliminate the need for immunosuppressive drugs

We are driven not only by scientific opportunity, but also by the urgent need for better long-term solutions for individuals living with Type 1 and Type 2 diabetes.

From Academic Discovery to Biotech Startup

Regenerative Medical Solutions was founded on more than 15 years of foundational diabetes research conducted in the laboratory of Dr. Jon Odorico at the University of Wisconsin–Madison. Dr. Odorico, a pancreatic replacement surgeon who began practicing at the University of Wisconsin Hospital in 1995, witnessed firsthand the limitations of organ transplantation due to the shortage of donor pancreases. This clinical experience led him to investigate regenerative approaches capable of replicating pancreatic function using stem cells.

In 2006, when Dr. Odorico’s daughter was diagnosed with Type 1 diabetes, his research efforts intensified with a renewed sense of urgency and purpose. His laboratory advanced novel techniques for differentiating human induced pluripotent stem cells into pancreatic islet-like cells, resulting in multiple granted and pending patents.

In 2012, these discoveries were translated into a commercial venture with the formation of RMS, a biotech company focused on advancing iPSC-based therapies from research to real-world application.

Today, RMS continues to build upon that academic legacy, combining scientific innovation with entrepreneurial execution, and remains dedicated to advancing stem cell therapy for diabetes.

The Science Behind Our iPSC Therapy

Induced pluripotent stem cells (iPSCs) are adult cells that have been reprogrammed to an embryonic-like state, allowing them to differentiate into many specialized cell types. iPSC therapy leverages this technology to generate specific functional cells for regenerative purposes.

At RMS, we have developed protocols to produce human induced pluripotent stem cell-derived Islet-Like Clusters (ILCs), cellular structures designed to mimic the insulin-producing beta cells of the pancreas.

iStock-2174865889

Our stem cell therapy research aims to:

  • Generate functional insulin-producing cells
  • Improve cell resilience and long-term performance
  • Overcome donor pancreas shortages
  • Enable scalable manufacturing processes

Unlike traditional pancreas or islet transplantation approaches that often require lifelong immunosuppressive therapy, RMS is developing its iPSC-based platform with the goal of eliminating the need for chronic immunosuppression. By addressing immune compatibility challenges at the cellular design level, we aim to improve long-term safety, broaden patient eligibility, and enhance quality of life.

Over 15 years of academic research followed by more than eight years of continued development at RMS has strengthened our differentiation protocols and intellectual property portfolio.

By combining regenerative medicine principles with translational biotech development, we are working toward a future where diabetes treatment moves beyond symptom management and toward cellular restoration.

Leadership Driven by Experience and Personal Commitment

RMS is led by a team of experienced scientists and business professionals with deep expertise in stem cell biology, pancreatic islet transplantation, and biotechnology company growth.

Dr. Jon Odorico, MD, FACS, is a world-renowned researcher and pancreatic replacement surgeon. His clinical and academic career spans decades of experience in islet biology, transplantation, and diabetes research. His personal connection to Type 1 diabetes further reinforces RMS’s patient-centered mission.

Our broader leadership team and expert advisors bring extensive experience in:

  • Biotechnology startup development
  • Strategic growth and partnerships
  • Intellectual property strategy
  • Commercialization pathways

This combination of scientific authority and business acumen positions RMS to responsibly advance regenerative medicine innovations toward clinical and commercial milestones.

Building Innovation in Madison’s Biotechnology Ecosystem

Regenerative Medical Solutions operates near Madison, Wisconsin, within one of the Midwest’s most dynamic life sciences communities. The region is home to leading research institutions, biotechnology companies in Madison WI, and a strong network of academic and industry collaborators. Our roots in the University of Wisconsin–Madison provide a strong scientific foundation, while our presence in the Madison innovation ecosystem supports continued growth, research collaboration, and talent development. While our origins are in Wisconsin, our mission is global. Diabetes is a worldwide health crisis, and our regenerative medicine platform is designed with scalability and international impact in mind.

Intellectual Property and Long-Term Vision

RMS has developed a strong and growing intellectual property portfolio, including multiple granted and pending patents related to stem cell differentiation and islet-like cluster development.

Our long-term vision includes:

  • Advancing iPSC-based therapies toward clinical evaluation
  • Expanding applications for drug discovery and research tools
  • Forming strategic partnerships within the global biotechnology sector
  • Delivering innovative regenerative medicine solutions responsibly and ethically

We recognize that the path to a diabetes cure requires scientific rigor, regulatory diligence, and sustained collaboration. Our commitment is to advance this work methodically, transparently, and with the highest standards of research integrity.

In addition to advancing our proprietary regenerative medicine platform, RMS also provides specialized life science consulting services, supporting biotechnology companies and research organizations with expertise in stem cell development, translational strategy, and product advancement.

Advancing the Future of Diabetes Treatment

Regenerative Medical Solutions was founded on the belief that regenerative medicine can fundamentally transform how diabetes is treated. By combining world-class academic research, proprietary stem cell technologies, and experienced leadership, we are building a biotechnology company focused on long-term impact.

Our mission is ambitious but grounded in science: to develop innovative stem cell therapy approaches that may one day redefine what is possible in diabetes treatment.

Through collaboration, perseverance, and scientific excellence, RMS continues to work toward a future where restoring natural insulin production becomes a reality for patients worldwide.

Contact Us

leadership team

Anthony Kolton

President and CEO

Jon Odorico, M.D., F.A.C.S

Co-Founder, Scientist

Tom Joyce

Vice president